Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
ZYME
Zymeworks Inc.
Zymeworks develops oncology therapeutics, including zanidatamab and multiple ADC/MSAT platform programs.
|
$2.05B |
$27.34
+4.43%
|
|
GLPG
Galapagos N.V.
Core product category: CAR-T and other cell therapies (cell therapy platform).
|
$2.05B |
$31.14
+0.06%
|
|
SRPT
Sarepta Therapeutics, Inc.
Directly develops gene therapies (ELEVIDYS) and other gene therapy programs; gene therapy is Sarepta's core biotech focus.
|
$2.05B |
$20.97
+8.37%
|
|
HRMY
Harmony Biosciences Holdings, Inc.
Harmony's WAKIX and pipeline assets target rare neurological diseases, aligning with Biotech - Rare Diseases.
|
$2.05B |
$35.59
+0.71%
|
|
VCEL
Vericel Corporation
Vericel's core offerings are autologous cell therapies (MACI and Epicel), placing the company in the cell therapy space.
|
$2.04B |
$40.32
-5.22%
|
|
IMCR
Immunocore Holdings plc
KIMMTRAK is an oncology immunotherapy (melanoma) core product; Immunocore's pipeline expands the platform into oncology.
|
$2.02B |
$39.99
+0.31%
|
|
IBRX
ImmunityBio, Inc.
Lead oncology-focused biotechnology with ANKTIVA and cancer immunotherapy platforms.
|
$2.01B |
$2.12
+2.16%
|
|
OGN
Organon & Co.
Directly manufactures/markets medical devices (Nexplanon implant and Jada System) used in women's health and obstetric care.
|
$2.01B |
$7.75
+3.20%
|
|
MESO
Mesoblast Limited
Direct product category: allogeneic mesenchymal lineage cell therapy platform and approved product Ryoncil.
|
$2.00B |
$17.36
+8.09%
|
|
SKWD
Skyward Specialty Insurance Group, Inc.
Accident & Health activities include health insurance lines (group stop-loss and related A&H offerings).
|
$1.98B |
$48.98
-0.64%
|
|
ESTA
Establishment Labs Holdings Inc.
Motiva implants, tissue expanders, and related breast prosthetic devices are the core product line, i.e., prosthetics & implants.
|
$1.97B |
$67.91
-1.58%
|
|
GPCR
Structure Therapeutics Inc.
Company focuses on developing oral small-molecule GPCR-targeted therapeutics, including lead GLP-1R agonist and other oral GPCR modulators.
|
$1.97B |
$34.20
+0.09%
|
|
AVAH
Aveanna Healthcare Holdings Inc.
AVAH directly provides Home Health and Hospice services to patients in home settings.
|
$1.94B |
$9.28
+0.54%
|
|
SION
Sionna Therapeutics, Inc.
Lead candidates are oral small-molecule therapeutics (SION-719, SION-451) in clinical development.
|
$1.93B |
$43.83
-1.02%
|
|
OLMA
Olema Pharmaceuticals, Inc.
Palazestrant and OP-3136 are oral small-molecule therapeutics developed for cancer, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.93B |
$28.12
+7.86%
|
|
KN
Knowles Corporation
Knowles has a significant MedTech / medical device presence via advanced microphones and related audio components used in medical devices.
|
$1.93B |
$22.43
+0.02%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
|
$1.91B |
$4.41
+0.80%
|
|
TWST
Twist Bioscience Corporation
Twist's antibody libraries for drug discovery align with the Antibody Discovery Platform investable theme.
|
$1.91B |
$31.66
+1.77%
|
|
SEM
Select Medical Holdings Corporation
Direct hospital services provider; SEM's core revenue comes from Hospital Services including inpatient rehabilitation and CIRH.
|
$1.91B |
$15.43
-0.90%
|
|
LMAT
LeMaitre Vascular, Inc.
Directly produces vascular interventional devices (grafts, patches, shunts, catheters) used in vascular surgery.
|
$1.89B |
$83.44
-0.06%
|
|
QDEL
QuidelOrtho Corporation
QuidelOrtho directly develops diagnostic instruments and platforms (including molecular diagnostics platforms) used in labs, aligning with Diagnostic Equipment.
|
$1.87B |
$27.53
-2.15%
|
|
PRGO
Perrigo Company plc
Digestive Health OTC products are a significant Perrigo self-care category.
|
$1.85B |
$13.43
+3.95%
|
|
ANIP
ANI Pharmaceuticals, Inc.
ANI's Rare Disease/Brands expansion includes ophthalmic therapies ILUVIEN and YUTIQ acquired via Alimera, marking Ophthalmic Drugs as a direct product category.
|
$1.83B |
$84.37
+1.38%
|
|
SYRE
Spyre Therapeutics, Inc.
Spyre's pipeline comprises engineered monoclonal antibodies (SPY001/SPY002/SPY003) targeting α4β7, TL1A, and IL-23 for IBD and RA.
|
$1.80B |
$29.77
+1.95%
|
|
ATRC
AtriCure, Inc.
AtriCure directly manufactures surgical equipment and devices used in operating rooms and minimally invasive cardiac procedures.
|
$1.79B |
$36.02
-6.39%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$1.78B |
$26.80
+1.34%
|
|
PRCT
PROCEPT BioRobotics Corporation
PROCEPT's Aquablation robotic systems are surgical equipment sold for urology procedures.
|
$1.76B |
$31.68
-1.83%
|
|
PAHC
Phibro Animal Health Corporation
Vaccines are explicitly listed as a pillar of the Animal Health segment.
|
$1.75B |
$43.23
-2.21%
|
|
ENOV
Enovis Corporation
Directly produces orthopedic devices and implants used in reconstructive surgery.
|
$1.73B |
$30.34
-0.31%
|
|
UFPT
UFP Technologies, Inc.
Design and manufacture of customized components and subsystems used in medical devices (foams, films, plastics, fabrics, die-cut parts, and assembly).
|
$1.73B |
$223.94
-2.53%
|
Showing page 11 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
